NASDAQ · SERVICES-MISC HEALTH & ALLIED SERVICES, NEC · SMALL CAP
Biorestorative Therapies, Inc. BRTX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$359,700
▼ 10.3% vs FY2024
EPS · FY25
$-1.58
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-320.5%
Net margin · FY25
-3959.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 359,700.00
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 3959 cents on every revenue dollar this year.
Per share
USD -1.58
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-320.5%
Return on equity, FY2025
ROE
Operating margin-4350.1%
Net margin-3959.4%
Return on assets-174.1%
Each USD of equity lost 320 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -3.1M
Share of profit-0.0%
Consecutive raises—
Growth
+36.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+44.3%
+36.1%
−5.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 4.1M
total assets, end of FY2025
Total assetsUSD 4.1M
EquityUSD 356,744.00
CashUSD 1.5M
Current ratio0.84×
Equity funds 9% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
·
·
·
·
·
·
·
·
·
·
0.0
0.0
0.0
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.58
−1.16
−2.47
−3.65
−37.30
−28.56
−0.66
−1.64
−1.74
−2.10
−3.20
−4.38
−0.35
−0.48
−0.01
0.00
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−320.5
−96.9
−102.7
−125.5
−937.5
·
·
·
·
·
·
·
·
·
·
·
·
Shares out B
0.01
0.01
0.00
0.00
0.00
0.00
0.08
0.01
0.01
0.00
0.00
0.00
0.02
0.01
0.61
0.43
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
55 of 55
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed